GlobeNewswire 01/12/2021 Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating ...

GlobeNewswire 15/10/2021 Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PN...

GlobeNewswire 07/09/2021 Nature Medicine publishes positive phase 3 anakinra study results in patients with COVID-19 pneumoni...

GlobeNewswire 08/07/2021 Amolyt Pharma Announces Appointment of Two Directors

GlobeNewswire 25/05/2021 Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcet...

GlobeNewswire 19/05/2021 DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Ap...

GlobeNewswire 17/03/2021 Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Compar...

GlobeNewswire 22/12/2020 FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA)

GlobeNewswire 10/12/2020 Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegc...

GlobeNewswire 19/11/2020 Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacopl...

GlobeNewswire 02/11/2020 Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results

GlobeNewswire 27/10/2020 Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of System...

GlobeNewswire 30/09/2020 Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Support...

GlobeNewswire 23/09/2020 First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory ...

GlobeNewswire 16/09/2020 FDA Granted Pediatric Disease Designation for OXi-4503

GlobeNewswire 08/09/2020 Selecta Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire 01/09/2020 Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Val...

GlobeNewswire 03/08/2020 Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer

GlobeNewswire 03/08/2020 Selecta Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire 30/07/2020 Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter Financial Results ...

GlobeNewswire 28/07/2020 Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212,...

GlobeNewswire 18/06/2020 Sarepta Therapeutics and Selecta Biosciences Enter into Research License and Option Agreement for Se...

GlobeNewswire 18/06/2020 Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Se...

GlobeNewswire 15/06/2020 Selecta Biosciences to Present at the Raymond James 2020 Human Healthcare Innovation Conference